Drug Trial Radar · NCT07359872
Relaxin Therapy for Atrial Fibrillation
Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Dec 31, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Deeptankar DeMazumderFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Relaxera Pharmaceuticals; McGowan Institute for Regenerative Medicine, University of Pittsburgh; Relaxera Pharmazeutische Gesellschaft mbH & Co. KG
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atrial fibrillation (AF) is the most common heart rhythm disorder. The presence of AF increases the risk of death and is associated with a 5-6-fold increase in stroke incidence, due almost exclusively to thrombus formation in the heart. Current therapies for AF are limited. The evaluation of new, more effective treatments for preventing AF recurrence remains a critical unmet clinical need. AF is considered a progressive disease that increases in prevalence with age and can convert from "paroxysmal" to "persistent" to "permanent" AF in a single individual. This progression results, in part, from high oxidative stress and progressive adverse electrical changes in the heart. Compelling preclinical and clinical data indicate that Relaxin, a naturally occurring peptide hormone, may reverse the electrical remodeling. Thus, our overall objective is to investigate the effects of Relaxin in Veterans who have failed medical management for symptomatic AF and is referred to Cardiac Electrophysiology Laboratory for catheter ablation and pulmonary vein isolation. We will determine whether Relaxin therapy, in addition to the standard of care, counteracts the oxidative stress-related electrical derangement and reduces the post-ablation AF burden. A unique aspect of this proposal is that it is based in part on observations derived from the basic, translational and computational labs of the PI and co-investigators and from the observations by the PI while caring for patients with AF. As such, this proposal represents a true progression from the bench to the bedside. If successful, our findings may lead to the design of a new, more effective treatment for a major unmet public health problem in the United States as well as the world.
Conditions
- Atrial Fibrillation (AF)
- Arrhythmia
- Oxidative Stress
- Stroke
- Major Cardiovascular Event
- Heart Failure
- Catheter Ablation
- Ablation of Atrial Fibrillation
Interventions
RelaxinDrug
subcutaneous injections of Relaxin once daily
PlaceboDrug
subcutaneous injections of Placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0Time frame: 390 days
- Ratio of the average daily AF burden before and after treatmentTime frame: 390 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.